anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Amino acid based ORS/medical food (VS002A). Initial treatment dosing with VS002A will be estimated using body weight in accordance with 5-10 ml/kg after each loose stool as per icddr,b guidelines, to maintain ongoing loss.
Chronic inflammation is a major cause of cancer worldwide. Interleukin 33 (IL-33) is a critical initiator of cancer-prone chronic inflammation; however, its induction mechanism by environmental causes of chronic inflammation is unknown. Herein, we demonstrate that Toll-like receptor (TLR)3/4-TBK1-IRF3 pathway activation links environmental insults to IL-33 induction in the skin and pancreas inflammation. An FDA-approved drug library screen identifies pitavastatin to effectively suppress IL-33 expression by blocking TBK1 membrane recruitment/activation through the mevalonate pathway inhibition. Accordingly, pitavastatin prevents chronic pancreatitis and its cancer sequela in an IL-33-dependent manner. The IRF3-IL-33 axis is highly active in chronic pancreatitis and its associated pancreatic cancer in humans. Interestingly, pitavastatin use correlates with a significantly reduced risk of chronic pancreatitis and pancreatic cancer in patients. Our findings demonstrate that blocking the TBK1-IRF3-IL-33 signaling axis suppresses cancer-prone chronic inflammation. Statins present a safe and effective prophylactic strategy to prevent chronic inflammation and its cancer sequela.
I present a patient with trisomy 18 associated with neuroblastoma. To the best of my knowledge, this is the second report of such an individual in the relevant literature. A 19-month-old girl known to have trisomy 18 presented with respiratory distress secondary to pleural effusion. Work-up showed metastatic neuroblastoma to multiple sites, and the patient's clinical situation was critical. The physician-parent's decision was not to proceed with treatment of the malignancy. Based on this report, I recommend that physicians remain vigilant and have a high level of suspicion about the potential association between neuroblastoma and trisomy 18. Accordingly, it may be necessary to consider performing serial abdominal ultrasounds and biochemical tests to screen children with trisomy 18 who survive beyond infancy.
INTRODUCTION: Various randomized control trials in the pediatric population have shown no therapeutic advantage of video-assisted thoracoscopic surgery over fibrinolytic therapy (tissue plasminogen activator [tPA]) for empyema management. However, literature detailing changes in practice management and protocol implementation is limited. In 2018, we instituted clinical practice guidelines (CPGs) for empyema management utilizing tissue plasminogen activatorinstillation via a small bore chest tube as initial therapy. Before standardization, surgeon preference drove management. Our aim was to determine differences in management and outcomes following institutional CPG implementation.
METHODS: A single-institution retrospective study (2002-2022) examined patients 0-18 y of age diagnosed with pneumonia and associated empyema (loculated pleural fluid on ultrasound or computed-tomographic scan). The comparison groups were pre- and post-CPG implementation groups. Comparative statistics were performed, and the significance level was set at P < 0.05.
RESULTS: Sixty-one patients met the inclusion criteria: 33 (54%) preimplementation and 28 (46%) postimplementation. The demographics and diagnostic imaging modalities were similar between groups. There were no significant differences in time to initiate antibiotics, antibiotic duration, intensive care unit length of stay (LOS), or total hospital LOS. The utilization of video-assisted thoracoscopic surgery as initial intervention significantly decreased from 66% to 10% after protocol implementation (P < 0.01); the failure rates of initial therapy choice were similar (12% versus 10%, P = 0.87). Marked reduction in total patients undergoing operative intervention at any point during the course of therapy was observed, 76% preimplementation versus 21% postimplementation (P < 0.01).
CONCLUSIONS: In children treated for empyema, the overall incidence of operative intervention significantly decreased following CPG implementation. The changes in antibiotic usage, intensive care unit/total LOS, and initial therapy failure rates did not differ. In our experience, the implementation of a CPG was instrumental in adherence to national guidelines.
A replication-defective recombinant virus, preferably an adenovirus that lacks E1a, E1b and E4 ORF 6, capable of infecting an eye and containing a ORF encoding a protein that when expressed in lens epithelial cells of an eye, suppresses, at the level of the germinative epithelium of the lens of the eye, cellular proliferation which is stimulated by eye surgery and which would otherwise result in secondary cataract formation in the eye is disclosed. The ORF, to be expressed, is under the control of a promoter sequence which is expressly exclusively in human lens epithelial cells. The preferred ORFs, to be expressed, include a non-phosphorylatable retinoblastoma ORF, a dominant negative mutant of a human RAS ORF and a Herpes thymidine kinase ORF. The preferred promoter sequences include: a) a promoter of a human Major Intrinsic Protein gene, particularly from −259 nt to +34 nt, b) a promoter of a human β crystallin gene, particularly from −345 nt to +45 nt, and especially c) the promoter of the Major Intrinsic Protein gene or β crystallin gene or portions thereof, in combination with elements of the promoter of the rat Early Growth Response-1 gene, from −518 nt to −236 nt. Use of the recombinant virus for the treatment of an eye, undergoing eye (e.g. cataract) surgery, in order to reduce the incidence of cellular proliferation in the eye following the surgery, and thereby to prevent the formation of secondary cataracts is disclosed.
PROBLEM TO BE SOLVED: To obtain an oil-in-water type emulsion composition exhibiting excellent stability at high temperature and usability. SOLUTION: This oil-in-water type emulsion composition is obtained by including a hydrophilic nonionic surfactant, a higher aliphatic alcohol, water and an oil content and characterized by satisfying the conditions of the followings (1)-(4). (1): A gel is formed from the hydrophilic nonionic surfactant, the higher aliphatic alcohol and water and the transition temperature of the formed gel is higher than 60 deg.C. (2): The formulation amount of the hydrophilic nonionic surfactant is 0.2-1.0 wt.% based on the whole weight of the oil-in-water type emulsion composition. (3): The mole ratio between the formulation amounts of the hydrophilic nonionic surfactant forming the above gel and the higher aliphatic alcohol is 1:3. (4): An excessive higher aliphatic alcohol not participating in gel formation or an amphiphilic substance is included in a formulation amount of 1-10 wt.%.
Chronic hepatitis B (CHB) mainly causes cirrhosis and hepatocellular carcinoma (HCC). Metabolic fatty liver disease (MAFLD) has become the most common chronic liver disease worldwide with the continuous changes in lifestyle and dietary patterns and the increase in the number of obese individuals. Consequently, the incidence rate of CHB combined with MAFLD is rapidly increasing. However, the pathogenesis, treatment, and clinical prognosis remain unclear due to the interaction between CHB and MAFLD. Notably, in the academic community, there are still controversies as to whether patients with CHB and MAFLD should immediately start antiviral treatment, whether MAFLD affects the antiviral efficacy in CHB patients, and whether nucleos(t)ide analogues (NAs) affect the body's metabolism. This article reviews the epidemiology, clinical prognosis, treatment management strategies (especially the antiviral efficacy of NAs drugs), and NAs drug effects on the body's metabolism in patients with CHB combined with MAFLD so as to provide diagnostic and therapeutic concept for clinicians.
<P>PROBLEM TO BE SOLVED: To solve problems such that since a skin fixed by a plaster cast, etc., is placed under a closure environment over a long period, and bacteria proliferate on the skin surface caused by sweat and dirt to easily cause smell and itchiness.  <P>SOLUTION: This aerosol composition for a skin closure environment is provided by incorporating 5-10 pts.wt. lower alcohol, 10-35 pts.wt. water, 0.05-15 pts.wt. medicine for the skin and 50-70 pts.wt. propellant. Also, the aerosol for the skin closure environment is prepared by filling the aerosol composition in a hermetically closed container. By inserting an extension tube 4, etc., into the skin closure environment, the aerosol composition is supplied by ejecting the composition. A suitable cooling effect is produced in the skin closure environment and it is possible to dissolve uncomfortable feeling by generated itchiness, last the inhibiting effect of the itchiness and also exhibit a good deodorizing effect.  <P>COPYRIGHT: (C)2007,JPO&INPIT
The invention relates to compounds with the formula where the substituted have the meanings listed in the description, and to their pharmaceutically acceptable salts. They are forms intensifying the secretion of the growth hormone (secretagogues) and raising the levels of endogenous growth hormone. The compounds are useful for the treatment and prevention of osteoporosis, congestive cardiac insufficiency and weakness related to old age and obseity, acceleration of the strengthening of the osteal fracture, reduction of theprotein catabolytic reactions after a serious operation, reduction of the cachexia and theloss of protein as a result of chronic diseases, acceleration of the healing of wounds or of the restoration of burn patients or such undergoing a heavy operation, improvement of the muscular strength, mobility, maintainance of the skin thickness, metabolytic homeostasis and renal homeostasis. The compounds can also be used for the treatment of osteoporosis when applied in combination with a bisphosphonate compound such as alendronate, estrogen, premarin and optionally progesteron, estrogen agonist are antagonist, or calcitonin and useful to this pharmaceutical compositions. The invention also relates to pharmaceutical compositions which are useful for increasing the endogenous production or release of the growth hormon in humans or animals the compositions of which contain an effective above compound and form, intensifying the growth hormone secretion selected among GHRP-6, Hexarelin, GHRP-1, factor of releasing the growth hormone (GRF), IGF-1, IGF-2, B-HT920. The invention also relates to intermediate compounds useful for the preparation of the compounds having the above formula. 94 claims
FIELD: cosmetology. SUBSTANCE: cosmetic agent has the following ratio of components, wt. %: aqueous extract of peat mud, 90-95; polymer of rarely-joined acrylic acid, 0.6-0.8; aqueous solution of mineral salts, the balance. Aqueous extract of peat mud is prepared by extraction of aqueous solution of mineral salts of suspension dried at temperature not more 80 C from mixture of peat mud and aqueous solution of mineral salts. Proposed gel may be used as a skin moisturizing agent, and also as nourishing, massage, antiinflammatory and resorpting preparation. EFFECT: improved quality. 3 ex
Subjects will undergo the Brain-Computer Interface Intervention for 24 sessions over the span of 8 weeks. Each session will take 30-minute to complete. The intervention group will undergo the intervention in the first 8 weeks of the trial.
Omega 3 fatty acids for 6 months and then off omega 3 fatty acids for the next 6 months. In the first 6 months, you will be asked to take one capsule of Omega 3 fatty acids with breakfast and 1 with dinner/day for the first week, 2 capsules in the morning and one capsule in the evening for the second week and then 2 capsules with breakfast and 2 with dinner/day for the remaining 24 weeks. In the next 6 months (Months 7 to 12), you will have a blood test for markers of inflammation at the end of Month 7 and at Month 9 and 12 to determine if the anti-inflammatory effects of Omega 3 acids are still there after you have stopped taking it.
A controlled release formulation useful in the treatment and/or prevention of cardiac disaeses is disclosed. The formulation comprises a therapeutically effective amount of carvedilol or its pharmaceutically acceptable salt, matrix-foming polymer, solubility enhancer and excipients. The matrix-foming polymer comprises one or more selected from 20-60%wt of Methocel K15M, 15-20%wt of Methocel K100M, 25-35%wt of Methocel E4M, 35-45%wt of Eudragit RSPO or 35-55%wt of WSR N12NF. The solubility enhancer comprises one or more selected from 25-55%wt of povidone, 25-35%wt of PEG6000 or 35-45%wt of HPC-L. The excipient comprises one or more selected from 15-35%wt of corn starch or 0.1-2%wt of magnesium stearate. In an embodiment, the formulation includes two or more sub units having with release profiles.
Physicians, nurses and orthopedic officers who staff the emergency intake and orthopedic procedure area of HEAL hospital, Goma DRC, Black Lion Hospital, Addis Ababa and Kindu General Hospital in Kindu DRC. These participants recorded their nerve block intervention over one year for pain management and assessed patient pain level after 10 cc lidocaine.
Group 1 (experimental group): Subjects will be given an elimination diet based upon foods with a positive antibody profile in the Biomerica InFoods® IBS test. The elimination diet will also exclude any and all foods to which the subject has a known IgE allergy and foods the subject already currently eliminates.
OBJECTIVE: Currently, there is no risk scores built to predict risk in thoracic aortic surgery. This study aims to develop and internally validate a risk prediction score for patients who require arch reconstruction with hypothermic circulatory arrest.
METHODS: From 2002 to 2018, data for 2270 patients who underwent aortic arch surgery in 12 institutions in Canada were retrospectively collected. The outcomes modeled included in-hospital mortality and a modified Society of Thoracic Surgeons-defined composite for mortality or major morbidity. Multivariable logistic regression using least absolute shrinkage and selection operator selection method and mixed-effect regression model was used to select the predictors. Internal calibration of the final models is presented with an observed-versus-predicted plot.
RESULTS: There were 182 in-hospital deaths (8.0%), and the incidence of Society of Thoracic Surgeons-defined composite for mortality or major morbidity was 27.9%. Variables that increased risk of mortality are age, chronic obstructive pulmonary disease, atrial fibrillation, peripheral vascular disease, New York Heart Association class ≥III symptoms, acute aortic dissection or rupture, use of elephant trunk, concomitant surgery, and increased cardiopulmonary bypass time, with median c-statistics of 0.85 on internal validation. The c-statistics was 0.77 for the model predicting Society of Thoracic Surgeons-defined composite. Internal assessment shows good overall calibration for both models.
CONCLUSIONS: We developed and internally validated a risk score for patients undergoing arch surgery requiring hypothermic circulatory arrest using a multicenter database. Once externally validated, the ARCH (Arch Reconstruction under Circulatory arrest with Hypothermia) score would allow for better patient risk-stratification and aid in the decision-making process for surgeons and patient prior to surgery.
Clinical studies of PROAIR HFA Inhalation Aerosol did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. Other reported clinical experience has not identified differences in responses between elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy . [see ] , Warnings and Precautions (5.45.7)

All beta -adrenergic agonists, including albuterol, are known to be substantially excreted by the kidney, and the risk of toxic reactions may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. 2
OBJECTIVES: I. Determine the safety, tolerability, maximum tolerated dose, and dose limiting toxicity of oral SCH 66336 with fluorouracil and leucovorin calcium in patients with advanced malignancy. II. Assess the multiple dose pharmacokinetics of oral SCH 66336 when administered with fluorouracil and leucovorin calcium. III. Assess the pharmacokinetics of fluorouracil when administered with oral SCH 66336. IV. Assess antitumor activity of oral SCH 66336 with fluorouracil and leucovorin calcium in these patients.

OUTLINE: This is a dose escalation study of SCH 66336. Patients receive oral SCH 66336 twice daily for 56 days. Patients receive leucovorin calcium IV over 1-2 minutes immediately followed by fluorouracil IV over 1-2 minutes on days 1, 8, 15, 22, 29, and 36. Courses repeat every 56 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of SCH 66336. The maximum tolerated dose is defined as the dose at which no more than 1 of 6 patients experiences dose limiting toxicity (DLT) during course 1, with at least 2 patients experiencing DLT at the next higher level.

PROJECTED ACCRUAL: Approximately 25 patients will be accrued for this study.
The development of a potentially life-threatening serotonin syndrome or Neuroleptic Malignant Syndrome (NMS)-like reactions have been reported with SNRIs and SSRIs alone, including venlafaxine hydrochloride extended-release capsule treatment, but particularly with concomitant use of serotonergic drugs (including triptans) with drugs which impair metabolism of serotonin (including MAOIs), or with antipsychotics or other dopamine antagonists. Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, coma), autonomic instability (e.g., tachycardia, labile blood pressure, hyperthermia), neuromuscular aberrations (e.g., hyperreflexia, incoordination) and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea) (see PRECAUTIONS, Drug Interactions). Serotonin syndrome, in its most severe form can resemble neuroleptic malignant syndrome, which includes hyperthermia, muscle rigidity, autonomic instability with possible rapid fluctuation of vital signs, and mental status changes. Patients should be monitored for the emergence of serotonin syndrome or NMS-like signs and symptoms. 

The concomitant use of venlafaxine hydrochloride extended-release capsules with MAOIs intended to treat depression is contraindicated (see CONTRAINDICATIONS and WARNINGS, Potential for Interaction with Monoamine Oxidase Inhibitors). 

If concomitant treatment of venlafaxine hydrochloride extended-release capsules with a 5-hydroxytryptamine receptor agonist (triptan) is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see PRECAUTIONS, Drug Interactions). 

The concomitant use of venlafaxine hydrochloride extended-release capsules with serotonin precursors (such as tryptophan) is not recommended (see PRECAUTIONS, Drug Interactions). 

Treatment with venlafaxine hydrochloride extended-release capsules and any concomitant serotonergic or antidopaminergic agents, including antipsychotics, should be discontinued immediately if the above events occur and supportive symptomatic treatment should be initiated.
Participants will receive oral ferrous sulfate tablets, 325mg (65mg elemental iron). Tablets are to be taken once daily for 3-6 months prior to surgery as time allows.
PWS is a complex neurobehavioral syndrome. Clinical features include obesity, increased appetite, low muscle tone, cognitive impairment, distinct behavioral features, hypogonadism, and neonatal failure-to-thrive. It is the most commonly recognized genetic cause of obesity; however, many obese children do not in fact have PWS. These individuals are therefore diagnosed with EMO, a condition that shares features with PWS. The development of new advances and strategies for treating PWS and EMO requires a thorough understanding of the conditions at both the clinical and molecular levels. One goal of this study is to collect long-term data on individuals with PWS and EMO in order to gain a better understanding of the natural progression of the conditions, from the neonatal period well into adulthood. Specific to PWS, this study will establish a genotype-phenotype correlation among the different sub-types and will evaluate the effects of growth hormone treatment on disease progression. Lastly, the study will compare PWS with EMO in terms of clinical features and genetic basis.

Participation in this natural history study will entail an initial evaluation, followed by yearly study visits until the age of 3 and then every 2 years thereafter. Each study visit will last between 3 and 4 hours, and will include a physical exam (including a DEXA scan to determine body composition), psychological testing, an interview with the study physician, and an evaluation of the participant's diet history. In addition, blood tests will be completed for genetic testing and photos will be taken to evaluate disease progression. Cognitive and behavioral assessments will also be conducted and will last between 10 and 30 minutes.
Chronic Kidney Disease (CKD) is a significant global health issue linked to dietary habits, especially high salt intake. However, the precise mechanisms driving this progression remain incompletely understood. This study reveals that a high-salt diet intensifies macrophage trained immunity, leading to a marked pro-inflammatory response upon repeated pathogenic exposures, as evidenced by increased renal damage and fibrosis. Under high-salt conditions, there was an induction of CD45+F4/80+ macrophage infiltration into the renal tissue, accompanied by heightened production of inflammatory cytokines. Distinct responses were observed between circulating and resident renal macrophages to a high-salt diet, with a notable upsurge in the migration of pro-inflammatory macrophages, driven by CCL2-CCR2 signaling and aberrant mTORC1 pathway activation. Treatment with rapamycin-liposome effectively reduced this inflammatory cascade by mitigating mTORC1 signaling. Transplantation of monocytes from CKD mice with a high-salt diet significantly exacerbates renal inflammatory damage in the host mice, showing increased migratory tendency and inflammatory activity. The cell co-culture experiment further confirmed that macrophages derived from CKD mice, particularly those under conditions of high salt exposure, significantly induced apoptosis and inflammatory responses in renal tubular cells. Taken together, recurrent exposure to LPS elicits the activation of trained immunity, consequently augmenting inflammatory response of monocytes/macrophages in the involved kidneys. The high-salt diet exacerbates this phenomenon, attributable at least in part to the overactivation of the mTORC1 pathway. This research emphasizes the importance of dietary modulation and targeted immunological interventions in slowing CKD progression, providing new insights into mTORC1-mediated pathophysiological mechanisms and potential management strategies for CKD.